Loading clinical trials...

UNKNOWNPHASE4

Emotions, Dopamine, Brain and Body

Influence of Domperidon on the Experience of Emotions, Brain and Bodily Activity

NCT06171087•German Institute of Human Nutrition

Summary

The study will examine the influence of domperidon (20mg) on brain and hebavioral responses to emotional stimuli (videos) using fMRI

Eligibility

Age

18 - 40 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•18-40 years old men and women
•Consent to participate
•Fluent in German
•Physically and mentally healthy. No regular medication
•BMI 18-25 kg/m2
•Alcohol consumption less than 15 glasses a week (wine / beer, a glass of higher-percentage alcohol counts as two glasses of beer)
•No illegal drug consumption in the week previous to the experiment
•No smoking
•No extreme athletes
•No vegetarians or vegans or any other dietary restrictions due to allergies or intolerances
+1 more criteria

Exclusion Criteria

•Former or current illnesses of:
•Brain or mind (including anxiety disorders, depression, eating disorders, personality disorders, alcohol, drugs or drug dependence, neurological disorders other than occasional headache, psychiatric or neurological abnormalities)
•Heart or blood circulation
•Gastro-intestinal or endocrine disorders
•Other serious past or present medical conditions (for example, metabolic syndrome, diabetes).
•Current medication and medication over a period of two weeks prior to the examination.
•Other serious health problems or present strong mental or physical stress.
•No current infection or excessive stress
•Missing consent to receive information about incidental findings from the MRI
•Tendency to claustrophobia, dizziness or panic attacks.
+11 more criteria

Locations (1)

German Institute of Human Nutrition

Potsdam, Brandenburg, Germany

Key Dates

Start Date

August 1, 2023

Primary Completion Date

March 30, 2024

Completion Date

September 30, 2024

Last Updated

December 14, 2023

Enrollment

ESTIMATED participants

Conditions

Emotions

Interventions

Domperidon

DRUG

Placebo

DRUG

Contacts

Ignacio Rebollo, PhD

CONTACT

0049 33200 8 ignacio.rebollo@dife.de

soyoung park, Prof PhD

CONTACT

0049 33200 88 soyoung.park@dife.de

Stories to Prevent (StoP) HPV Cancers

NCT06808776

Human Papillomavirus VaccinationEmotions

View study

RECRUITING

Neural Bases of Post-stroke Emotion Perception Disorders

NCT05595005

StrokeStroke Sequelae+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 14, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Emotions, Dopamine, Brain and Body

Inclusion Criteria

Exclusion Criteria

Stories to Prevent (StoP) HPV Cancers

Neural Bases of Post-stroke Emotion Perception Disorders

The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions

A Study of Effects of Expressive Writing on College Students Experiencing Psychological Difficulties

Effectiveness of Online Mindfulness Platform in Improving Anxiety, Depression, and Stress in Adult

Psychological and Physiological Effects of Different Objects of Breath Meditation